Kwality Pharmaceuticals Reports Strong Q2FY27 Results and Raises FY27 Revenue Guidance
Kwality Pharmaceuticals Ltd · Investor Presentation · 12 Nov 2026, 6:43 pm
Kwality Pharmaceuticals Reports Strong Q2FY27 Results and Raises FY27 Revenue Guidance Kwality Pharmaceuticals delivered robust Q2FY27 results, with revenue rising 62% YoY and 12% QoQ to ₹181.2 Cr. EBITDA surged 96% YoY to ₹49.8 Cr, with margins expanding to 27.5%, while PAT surged 106% YoY to ₹29.0 Cr. Strong execution and working capital discipline reduced the cash conversion cycle to 130 days in H1FY27. Following solid performance, management raised FY27 revenue guidance to ₹720+ Cr (from ₹700+ Cr) and targeted ₹1,000+ Cr by FY29, supported by ongoing capacity expansions in biologics, oncology, and hormones.
Original exchange filing (PDF)
More announcements from Kwality Pharmaceuticals Ltd
- Transcript of Earnings Conference Call - Q2FY2027 · 16 Nov 2026
- Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Recording of Investor/ Analyst Earnings Call held on November 13, 2026 · 14 Nov 2026
- Intimation under Regulation 30 of the SEBI(LODR), 2015 -Recording of Investor/ Analyst Earnings Call held on September 13, 2026 · 14 Nov 2026
- Appointment of new Statutory Auditors · 12 Nov 2026
- Resignation of Statutory Auditor · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026. · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026 · 12 Nov 2026
- Intimation of Earnings Conference Call for Q2 FY 2026-27 & REVISED LINK FOR REGISTRATION · 13 Nov 2026
